Designed to reinforce lucerastat as the first oral therapy suitable for all patients with Fabry disease, irrespective of their mutation type. The program is expected to support a potential regulatory ...

The funding supports Chiral’s mission to make post-silicon computing chips based on nanomaterials manufacturable at wafer scale and to unlock the next generation of chips beyond the limits of ...

This article is for informational purposes only. It is not medical advice. Weight management concerns should be evaluated by a qualified healthcare professional. Hims GLP-1 Weight Loss is a ...

CHARLOTTE, NC, Feb. 05, 2026 (GLOBE NEWSWIRE) -- His Choice Health today announced the upcoming opening of its newest clinic in Charlotte, targeted late February 2026, bringing its highly regarded, ...

Starting 2/2/16, the new Nashville location will offer partial hospitalization (PHP), intensive outpatient (IOP), and outpatient programs (OP), as well as sober living facilities, in Renaissance ...

Event: Biotricity Fiscal 2026 Third Quarter Financial Results and Business Update Call Date: Wednesday, February 11, 2026 Time: 4:30 PM ET (1:30 PM PT) Toll Free: 1-877-269-7751 International: ...

SAN CARLOS, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced that Company management will participate in a fireside ...

The FDA distinguishes between FDA-approved medications and compounded formulations. FDA-approved medications like Wegovy, Ozempic, Mounjaro, and Zepbound have undergone rigorous clinical trials for ...

Additionally, a webcast replay of the conference call will be available on the Investors section of the Company’s website following the call. Dentsply Sirona is the world’s largest diversified ...

Anaptys recently announced the intent to separate its biopharma operations from its substantial royalty assets by year-end 2026, enabling investors to align their investment philosophies and portfolio ...

Teknova will host a webcast and conference call on Thursday, February 26, 2026, beginning at 5:30 p.m. Eastern Time. To access the live webcast, listeners can log onto the call from the Investor ...

Adjusted EBITDA (non-GAAP) was $4.1 million for the fourth quarter of 2025, compared to a loss of $16.4 million for the fourth quarter of the prior year. Excluding revenue generated from the Genentech ...